Elutia (ELUT) Projected to Post Quarterly Earnings on Wednesday

Elutia (NASDAQ:ELUT) is projected to post its Q4 2025 results after the market closes on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $3.30 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 5:00 PM ET.

Elutia Stock Down 1.8%

Shares of ELUT stock opened at $1.09 on Monday. The company has a market capitalization of $46.54 million, a price-to-earnings ratio of -1.18 and a beta of 0.65. Elutia has a 12-month low of $0.50 and a 12-month high of $3.46. The firm has a fifty day moving average of $0.94 and a 200-day moving average of $0.99.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Elutia in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Elutia presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Insider Buying and Selling at Elutia

In related news, Director Kevin Rakin bought 70,000 shares of the stock in a transaction that occurred on Friday, January 30th. The shares were acquired at an average price of $1.06 per share, with a total value of $74,200.00. Following the completion of the transaction, the director owned 196,120 shares in the company, valued at $207,887.20. The trade was a 55.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Matthew Ferguson bought 60,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were bought at an average price of $0.53 per share, for a total transaction of $31,800.00. Following the acquisition, the chief financial officer directly owned 447,110 shares of the company’s stock, valued at $236,968.30. This represents a 15.50% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 255,500 shares of company stock worth $189,605 over the last quarter. Company insiders own 27.60% of the company’s stock.

Institutional Investors Weigh In On Elutia

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new position in Elutia during the fourth quarter worth $71,000. Renaissance Technologies LLC lifted its stake in Elutia by 64.7% in the fourth quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock valued at $71,000 after acquiring an additional 40,123 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Elutia in the 3rd quarter valued at about $50,000. Virtu Financial LLC bought a new position in shares of Elutia in the 3rd quarter valued at about $26,000. Finally, Deerfield Management Company L.P. acquired a new position in shares of Elutia during the 3rd quarter worth about $1,221,000. Institutional investors and hedge funds own 74.03% of the company’s stock.

Elutia Company Profile

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.